The first vaccine against respiratory syncytial virus (RSV) suitable for both infants and older adults has been approved by UK regulators.

A bivalent recombinant vaccine has been licensed by the Medicines and Healthcare products Regulatory Agency (MHRA) based on the results from two separate trials published earlier this year.

RSV causes up to 15,000 babies under six months to be hospitalised in England every year and in winter, as many as one in six of all UK hospital admissions of babies and children are due to bronchiolitis with 80% of cases are associated with RSV.

For older adults in the UK, it is estimated that RSV leads to 175,000 GP visits and 14,000 hospital admissions annually.

The vaccine prevented RSV-associated lower respiratory tract illness and RSV-associated acute respiratory illness in adults over 60 years of age.

Abrysvo has been authorised in infants from birth through 6 months of age following maternal immunisation during pregnancy and in adults 60 years of age and older.

If you wish to protect your self against this virus in the coming winter, please contact Dr Stewart at The Cademuir Clinic.